Azitra, Inc. (AZTR) Stock Analysis and Metrics

Azitra

NYSE: AZTR

$0.13 ▲ +0.00 (+2.04%)

At close: Jul 28, 2026 · 12:57 PM UTC

Financial Ratios

Market Cap2.02 Mn

P/E-0.17

Div. Yield0.00

ROIC (Qtr)-2.09

Add ratio to table…

About

Azitra, Inc. is an early stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary platform that includes a microbial library of approximately 1,500 unique bacterial strains isolated from human skin. This library is screened using artificial intelligence and machine learning tools developed in collaboration with researchers from Carnegie Mellon University to predict drug like molecules. A licensed genetic engineering technology from the Fred Hutchinson Cancer Center enables modification of previously intractable strains, expanding the range of microbes that can be engineered. Azitra’s lead product candidates are ATR 12 for Netherton syndrome, ATR 04 for EGFRi associated rash, and ATR 01 for ichthyosis vulgaris, each based on a genetically modified strain of Staphylococcus epidermidis designed to deliver therapeutic proteins directly to the skin.

Azitra, Inc. has not commenced commercial operations and does not generate revenue from product sales. The company has reported minimal service revenue related to research collaborations, such as a joint development agreement with Bayer that yielded seven thousand five hundred dollars in 2024 but none in 2025. Its primary financial support has come from a series of equity offerings, including an initial public offering in June 2023 and subsequent follow on placements, as well as draws on an equity line of credit with Alumni Capital LP. Until its pipeline candidates receive regulatory approval and reach the market, revenue generation will remain limited to these financing activities and occasional service income.

Azitra, Inc. occupies a pioneering niche in the field of live biotherapeutic products for dermatology, being among the first to engineer commensal skin bacteria for therapeutic use. The company’s pipeline targets rare and prevalent skin conditions that currently lack approved disease modifying therapies. For Netherton syndrome, competitors include Sixera Pharma which is investigating SXR 1096 and Quoin Pharmaceuticals which is investigating QRX 003, while for EGFRi associated rash emerging candidates are Hoth Therapeutics with HT 001 and Lutris Pharma with LUT 014. In the broader ichthyosis vulgaris market, most treatments are limited to symptomatic moisturizers and keratolytics, leaving a clear opening for a disease modifying approach. Azitra’s competitive advantages stem from its proprietary microbial library of over 1,500 strains, its AI/ML driven screening platform that predicts bioactive molecules from genetic sequences, and its exclusive worldwide license to the Fred Hutchinson Cancer Center’s SMPL technology, which enables genetic modification of previously intractable microbes. Together these capabilities allow the company to rapidly identify and engineer therapeutic candidates that few rivals can replicate, supporting a potential multi hundred million dollar opportunity for each lead program as noted in its internal projections.

The company intends to serve patients diagnosed with rare dermatologic conditions such as Netherton syndrome, EGFRi associated rash, and ichthyosis vulgaris, as well as the dermatologists and healthcare providers who treat these individuals. Based on publicly available estimates, Netherton syndrome affects roughly one to nine per hundred thousand people, which translates to a few thousand individuals in the United States alone. EGFRi associated rash occurs in up to eighty percent of patients receiving epidermal growth factor receptor inhibitor therapy for cancers such as colorectal or head and neck malignancies, representing a sizable subset of the hundreds of thousands of patients treated annually with these agents. Ichthyosis vulgaris has an estimated prevalence of one in two hundred fifty, corresponding to approximately 1.3 million people in the United States. While no commercial sales have occurred to date, the company’s future customer base will include patients seeking disease modifying therapies, physicians looking for effective adjunctive treatments, and payers interested in reducing the burden of chronic skin disease. Specific customer names have not been disclosed because the company remains in the pre revenue development stage.

Investment Thesis

▲ Bull case

Azitra is strategically leveraging its proprietary microbial genetic engineering platform to unlock significant near-term value creation opportunities beyond its core therapeutic pipeline, particularly through the ATR-COSF consumer initiative targeting the rapidly growing biotech cosmetic ingredients market. The company has identified a clear pathway to commercialization for its filaggrin protein and peptide technologies, which address widespread consumer concerns like fine lines, wrinkles, dry sensitive skin, and eczema-like rashes. With the biotech cosmetic market projected to grow from $2.3 billion in 2024 to $3.7 billion by 2030, Azitra's entry into this space represents a substantial de-risked revenue stream that could materialize significantly faster than traditional drug approval pathways. This diversification reduces reliance on the lengthy and uncertain clinical trial outcomes for ATR-12 and ATR-04, providing immediate cash flow potential while the therapeutic programs advance. The recent $10.5 million initial funding tranche from the securities purchase agreement, coupled with the potential for up to $20.9 million more upon warrant exercise, directly supports this cosmeceutical push, giving Azitra substantial runway to execute on this parallel value-creation strategy without dilutive near-term financing pressures.
The addition of MD Anderson Cancer Center as a sixth clinical site for the ATR-04 Phase 1/2 trial represents a meaningful catalyst that is likely underappreciated by the market in its potential to accelerate clinical development timelines. As a world-renowned oncology institution treating thousands of EGFR inhibitor therapy patients annually—where up to 80% experience associated rash—MD Anderson provides immediate access to a large, highly relevant patient population deeply motivated to find solutions that allow them to remain on effective cancer treatments. This site expansion directly addresses a critical bottleneck in rare disease and oncology-focused trials: patient enrollment speed. By securing a site with established infrastructure, expert investigators, and built-in referral networks for EGFRi-associated rash, Azitra is positioned to achieve faster dosing completion and earlier readouts than would be possible with community sites alone. The FDA's Fast Track designation for ATR-04 further amplifies the potential impact of accelerated enrollment, as it opens pathways for more frequent interactions with regulators and potential priority review, increasing the probability of a successful and timely path to market for this first-in-class topical live biotherapeutic.
Azitra's strengthened balance sheet following the March 2026 financing provides a critical runway to de-risk near-term operational milestones, with cash and cash equivalents reaching $10,051,003 as of March 31, 2026—a significant increase from $2,068,083 at December 31, 2025. This liquidity position directly funds research and development, general corporate expenses, and working capital needs, allowing the company to advance multiple pipeline programs in parallel without the immediate threat of financing constraints. Crucially, this cash buffer supports the completion of IND-enabling studies for ATR-01 targeting ichthyosis vulgaris (impacting 1.3 million in the U.S.), the topline readout from the Phase 1b trial for ATR-12 in Netherton syndrome, and the continued execution of the ATR-04 Phase 1/2 trial—all of which are anticipated as key 2026 milestones. The ability to fund these readouts internally reduces dependence on uncertain external financing and increases the likelihood of delivering positive data that could trigger partnership interest, regulatory engagement, or subsequent funding rounds at better terms.

Azitra is strategically leveraging its proprietary microbial genetic engineering platform to unlock significant near-term value creation opportunities beyond its core therapeutic pipeline, particularly through the ATR-COSF consumer initiative targeting the rapidly growing biotech cosmetic ingredients market. The company has identified a clear pathway to commercialization for its filaggrin protein and peptide technologies, which address widespread consumer concerns like fine lines, wrinkles, dry sensitive skin, and eczema-like rashes. With the biotech cosmetic market projected to grow from $2.3 billion in 2024 to $3.7 billion by 2030, Azitra's entry into this space represents a substantial de-risked revenue stream that could materialize significantly faster than traditional drug approval pathways. This diversification reduces reliance on the lengthy and uncertain clinical trial outcomes for ATR-12 and ATR-04, providing immediate cash flow potential while the therapeutic programs advance. The recent $10.5 million initial funding tranche from the securities purchase agreement, coupled with the potential for up to $20.9 million more upon warrant exercise, directly supports this cosmeceutical push, giving Azitra substantial runway to execute on this parallel value-creation strategy without dilutive near-term financing pressures.
The addition of MD Anderson Cancer Center as a sixth clinical site for the ATR-04 Phase 1/2 trial represents a meaningful catalyst that is likely underappreciated by the market in its potential to accelerate clinical development timelines. As a world-renowned oncology institution treating thousands of EGFR inhibitor therapy patients annually—where up to 80% experience associated rash—MD Anderson provides immediate access to a large, highly relevant patient population deeply motivated to find solutions that allow them to remain on effective cancer treatments. This site expansion directly addresses a critical bottleneck in rare disease and oncology-focused trials: patient enrollment speed. By securing a site with established infrastructure, expert investigators, and built-in referral networks for EGFRi-associated rash, Azitra is positioned to achieve faster dosing completion and earlier readouts than would be possible with community sites alone. The FDA's Fast Track designation for ATR-04 further amplifies the potential impact of accelerated enrollment, as it opens pathways for more frequent interactions with regulators and potential priority review, increasing the probability of a successful and timely path to market for this first-in-class topical live biotherapeutic.
Azitra's strengthened balance sheet following the March 2026 financing provides a critical runway to de-risk near-term operational milestones, with cash and cash equivalents reaching $10,051,003 as of March 31, 2026—a significant increase from $2,068,083 at December 31, 2025. This liquidity position directly funds research and development, general corporate expenses, and working capital needs, allowing the company to advance multiple pipeline programs in parallel without the immediate threat of financing constraints. Crucially, this cash buffer supports the completion of IND-enabling studies for ATR-01 targeting ichthyosis vulgaris (impacting 1.3 million in the U.S.), the topline readout from the Phase 1b trial for ATR-12 in Netherton syndrome, and the continued execution of the ATR-04 Phase 1/2 trial—all of which are anticipated as key 2026 milestones. The ability to fund these readouts internally reduces dependence on uncertain external financing and increases the likelihood of delivering positive data that could trigger partnership interest, regulatory engagement, or subsequent funding rounds at better terms.

▼ Bear case

Azitra faces significant and persistent challenges in achieving NYSE American continued listing compliance, which remains an underappreciated overhang despite the company's submitted plan. The exchange initially flagged non-compliance with Section 1003(a)(ii) requiring $4.0 million in stockholders' equity due to losses in three of four recent fiscal years, and later added a notice under Section 1003(a)(iii) requiring $6.0 million in equity given losses in five of five recent fiscal years. Although Azitra has until April 1, 2027 to regain compliance, the company's stockholders' equity stood at only $3,801,230 as of December 31, 2025, and while the March 31, 2026 balance sheet shows improvement to $10,480,283, this increase is largely driven by the recent preferred stock financing—which includes mandatory redemption-like features and warrants that could dilute future equity. The requirement to sustain compliance through the plan period means Azitra must not only reach but maintain the $6.0 million threshold through April 2027, a goal made precarious by its historical quarterly cash burn, which exceeded $3.9 million in Q1 2026 alone. Without sustained operational milestones that translate into meaningful revenue or cost efficiencies, the risk of delisting remains tangible, which would severely impair liquidity, increase financing costs, and damage institutional investor confidence.
The company's reliance on third-party manufacturers and clinical trial sites introduces material execution risks that are not sufficiently mitigated by its current operational scale, particularly as it seeks to advance multiple complex live biotherapeutic programs simultaneously. Azitra explicitly acknowledges dependence on third parties for product manufacturing, research, preclinical testing, and clinical testing in its risk disclosures—a vulnerability amplified by the novelty of its platform, which involves genetically engineered strains of S. epidermidis requiring specialized fermentation, formulation, and cold-chain logistics. Any disruption in these external partnerships—whether due to capacity constraints, quality control failures, or regulatory scrutiny of the manufacturing process—could delay critical milestones like the ATR-12 Phase 1b trial readout or ATR-04 dosing completion. Furthermore, the success of its cosmeceutical initiative hinges on scaling microbial fermentation for cosmetic-grade proteins and peptides, a process that may face unforeseen technical hurdles in purity, stability, or scalability that are not yet de-risked by pilot data. The lack of vertical integration in these critical functions means Azitra remains susceptible to bottlenecks outside its direct control, increasing the variance in expected timelines for value inflection points.
Despite the promising preclinical data for ATR-01 and the strategic expansion into cosmeceuticals, Azitra's core therapeutic programs continue to face steep clinical and regulatory hurdles that may be underestimated given the early-stage nature of its data. ATR-12, targeting the ultra-rare Netherton syndrome (estimated 20,000 global patients), remains in a Phase 1b trial with no published efficacy data to date, and the disease's complexity—driven by mutations in the SPINK5 gene leading to uncontrolled protease activity—has historically resisted therapeutic intervention. Similarly, while ATR-04 benefits from Fast Track designation for EGFR inhibitor-associated rash, the Phase 1/2 trial is still in early enrollment (targeting just eight patients in Cohort 1), and topical live biotherapeutics face unique regulatory scrutiny regarding long-term colonization risks, horizontal gene transfer concerns, and environmental safety—factors that could trigger unexpected FDA hold requests or require additional nonclinical studies. The company's historical inability to predictively translate early study results to later stages, combined with the absence of any approved microbiome-based dermatology therapeutics to date, creates a meaningful risk that clinical outcomes may not meet expectations, even if safety profiles remain favorable. Without near-term proof of concept in either program, the platform's value remains largely speculative.

Azitra faces significant and persistent challenges in achieving NYSE American continued listing compliance, which remains an underappreciated overhang despite the company's submitted plan. The exchange initially flagged non-compliance with Section 1003(a)(ii) requiring $4.0 million in stockholders' equity due to losses in three of four recent fiscal years, and later added a notice under Section 1003(a)(iii) requiring $6.0 million in equity given losses in five of five recent fiscal years. Although Azitra has until April 1, 2027 to regain compliance, the company's stockholders' equity stood at only $3,801,230 as of December 31, 2025, and while the March 31, 2026 balance sheet shows improvement to $10,480,283, this increase is largely driven by the recent preferred stock financing—which includes mandatory redemption-like features and warrants that could dilute future equity. The requirement to sustain compliance through the plan period means Azitra must not only reach but maintain the $6.0 million threshold through April 2027, a goal made precarious by its historical quarterly cash burn, which exceeded $3.9 million in Q1 2026 alone. Without sustained operational milestones that translate into meaningful revenue or cost efficiencies, the risk of delisting remains tangible, which would severely impair liquidity, increase financing costs, and damage institutional investor confidence.
The company's reliance on third-party manufacturers and clinical trial sites introduces material execution risks that are not sufficiently mitigated by its current operational scale, particularly as it seeks to advance multiple complex live biotherapeutic programs simultaneously. Azitra explicitly acknowledges dependence on third parties for product manufacturing, research, preclinical testing, and clinical testing in its risk disclosures—a vulnerability amplified by the novelty of its platform, which involves genetically engineered strains of S. epidermidis requiring specialized fermentation, formulation, and cold-chain logistics. Any disruption in these external partnerships—whether due to capacity constraints, quality control failures, or regulatory scrutiny of the manufacturing process—could delay critical milestones like the ATR-12 Phase 1b trial readout or ATR-04 dosing completion. Furthermore, the success of its cosmeceutical initiative hinges on scaling microbial fermentation for cosmetic-grade proteins and peptides, a process that may face unforeseen technical hurdles in purity, stability, or scalability that are not yet de-risked by pilot data. The lack of vertical integration in these critical functions means Azitra remains susceptible to bottlenecks outside its direct control, increasing the variance in expected timelines for value inflection points.
Despite the promising preclinical data for ATR-01 and the strategic expansion into cosmeceuticals, Azitra's core therapeutic programs continue to face steep clinical and regulatory hurdles that may be underestimated given the early-stage nature of its data. ATR-12, targeting the ultra-rare Netherton syndrome (estimated 20,000 global patients), remains in a Phase 1b trial with no published efficacy data to date, and the disease's complexity—driven by mutations in the SPINK5 gene leading to uncontrolled protease activity—has historically resisted therapeutic intervention. Similarly, while ATR-04 benefits from Fast Track designation for EGFR inhibitor-associated rash, the Phase 1/2 trial is still in early enrollment (targeting just eight patients in Cohort 1), and topical live biotherapeutics face unique regulatory scrutiny regarding long-term colonization risks, horizontal gene transfer concerns, and environmental safety—factors that could trigger unexpected FDA hold requests or require additional nonclinical studies. The company's historical inability to predictively translate early study results to later stages, combined with the absence of any approved microbiome-based dermatology therapeutics to date, creates a meaningful risk that clinical outcomes may not meet expectations, even if safety profiles remain favorable. Without near-term proof of concept in either program, the platform's value remains largely speculative.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	NBTX	Nanobiotix S.A.	1,780.80 Bn	0.00 Bn	57,370.43	0.11 Bn
2	AKTX	Akari Therapeutics Plc	979.03 Bn	0.00 Bn	-	-
3	ONC	BeOne Medicines Ltd.	472.52 Bn	0.00 Bn	82.33	0.96 Bn
4	VRTX	Vertex Pharmaceuticals Inc / Ma	123.43 Bn	0.00 Bn	10.10	-
5	REGN	Regeneron Pharmaceuticals, Inc.	71.56 Bn	0.00 Bn	4.80	1.99 Bn
6	BLTE	Belite Bio, Inc	62.37 Bn	-24.65 Bn	-	-
7	ARGX	Argenx Se	54.58 Bn	0.00 Bn	10.36	-
8	ALNY	Alnylam Pharmaceuticals, Inc.	38.11 Bn	0.00 Bn	8.89	-

Research Tools

Developers

About

Investment Thesis

Related and Nonrelated Parties Breakdown of Revenue (2023)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Related and Nonrelated Parties Breakdown of Revenue (2023)

Peer Comparison

Create an account

Sign In

Reset Password